Journal Publications
Project Data Sphere's success is ultimately measured by the practice-changing scientific insights discovered by the research community. We are proud to share the following list of peer-accepted publications, and we are grateful to the data providers, research scientists, and patients that make this possible.
| Author(s) |
Date |
Article Title | Journal |
|---|---|---|---|
|
Jie Zhou, Xun Jiang, Hong Amy Xia, Peng Wei, Brian P. Hobbs |
December 2021 | Predicting outcomes of phase III oncology trials with Bayesian mediation modeling of tumor response | Statistics in Medicine |
|
Kirill Zhudenkov, Sergey Gavrilov, Alina Sofronova, Oleg Stepanov, Nataliya Kudryashova, Gabriel Helmlinger, Kirill Peskov |
January 2022 | A workflow for the joint modeling of longitudinal and event data in the development of therapeutics: Tools, statistical methods, and diagnostics | ASCPT |
|
Xiang Yin, Pallavi S. Mishra-Kalyan, Rajeshwari Sridhara, Mark D. Stewart,Elizabeth A. Stuart, and Ruthanna C. Davi |
January 2022 | Exploring the Potential of External Control Arms created from Patient Level Data: A case study in non-small cell lung cancer | Journal of Biopharmaceutical Statistics |
|
Sophia Z Shalhout, Farees Saqlain, Kayla Wright, Oladayo Akinyemi, David M Miller |
January 2022 | Generalizable EHR-R-REDCap pipeline for a national multi-institutional rare tumor patient registry | Jamia Open |
|
Fadi S.Dahdaleh, Scott K.Sherman, Hunter D.D.Witmer, Ankit Dhiman, Rahul Rajeev, Elizabeth C.Poli, Fabian M.Johnston, Kiran K.Turagaa |
January 2022 | Potential evidence of peritoneal recurrence in Stage-II colon cancer from the control arm of CALGB9581 | The American Journal of Surgery |
|
Yu, Peter MD, ET AL |
February 2022 | Artificial Intelligence Comes of Age in the Fight Against Cancer | Oncology Times |
|
Liling Huang , Shiyu Jiang & Yuankai Shi |
February 2022 | Prognostic significance of baseline neutrophil–lymphocyte ratio in patients with non-small-cell lung cancer: a pooled analysis of open phase III clinical trial data | futuremedicine |
|
Deborah Plana, Geoffrey Fell, Brian M. Alexander, Adam C. Palmer & Peter K. Sorger |
February 2022 | Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects | Nature Communications |
|
Saki Nishiyama, Mamoru Narukawa |
February 2022 | Impact of the Economic Status of the Patient's Country of Residence on the Outcome of Oncology Clinical Trials | The Oncologist |
|
Ahmad Y. Abuhelwa, Sarah Badaoui, Hoi-Yee Yuen, Ross A. McKinnon, Warit Ruanglertboon, Kiran Shankaran, Anniepreet Tuteja, Michael J. Sorich & Ashley M. Hopkins |
February 2022 | A clinical scoring tool validated with machine learning for predicting severe hand–foot syndrome from sorafenib in hepatocellular carcinoma | Cancer Chemotherapy and Pharmacology |
|
Siddharth Ramchandran, Gleb Tikhonov, Otto Lönnroth, Pekka Tiikkainen, Harri Lähdesmäki |
March 2022 | Learning Conditional Variational Autoencoders with Missing Covariates | arXiv |
|
Steffen Ventz, Sean Khozin, Bill Louv, Jacob Sands, Patrick Y. Wen, Leah Comment, Brian M. Alexander, Lorenzo Trippa |
March 2022 | The Design and Evaluation of Hybrid Controlled Trials that Leverage External Data and Randomization | Research Square |
|
T.Elumalai, C.Barker, T.Elliott, J.Malik, A.Tran, A.Hudson, Y.P.Song, K.Patel, J.Lyons, P.Hoskin, A.Choudhury, H.Mistry |
March 2022 | Translation of Prognostic and Pharmacodynamic Biomarkers from Trial to Non-trial Patients with Metastatic Castration-resistant Prostate Cancer Treated with Docetaxel | Clinical Oncology |
|
Hiroyuki Saeki, Takuji Komeda, Risa Tanaka, Yuki Yamatani & Hironori Sakai |
March 2022 | Estimation of a Suitable Number of Patients for Selective Safety Data Collection (ICH E19 Draft Guideline): When is the Safety Profile of a Drug Well Characterized? | Therapeutic Innovation & Regulatory Science |
